Mike Paris
President/Chief Executive Officer
|
Michael Paris is an accomplished product development and operations executive with extensive experience in lifecycle management of innovative medical devices. He brings expertise in building and leading technology development and operations in early-stage ventures, as well as mature companies. Additionally, he has led and contributed to the successful regulatory authorizations (PMA and 510(k)) and commercial launch of numerous products. Prior to becoming CEO, Mr. Paris was Clinical Genomics’ Chief Operating Officer with oversight of all business subsidiaries. Prior to joining Clinical Genomics, he served as Chief Operating Officer and Senior Vice President, Operations and Technology Development, at Origin Inc., a biotechnology company. He had also held positions of increasing responsibility at Bioconnect Systems, a medical device company; Orthovita, Inc., which was acquired by Stryker Corporation in 2011, and Rex Medical, a medical device company specializing in the development, manufacturing, and marketing of innovative, minimally invasive medical devices. Mr. Paris received his BS degree in Mechanical Engineering Technology from Temple University, and an Executive MBA from Lebow College of Business, Drexel University.
|
Ed Rosen
Chief Strategy and Commercial Officer
|
Ed Rosen is an experienced global life sciences and oncology business leader with a proven track record in strategic planning, commercialization and P&L optimization. He has successfully led companies through periods of transformational growth, overseeing commercialization, innovation and product development across pharmaceutical, device and diagnostic businesses in key markets. He also brings a wealth of knowledge around health economics and reimbursement, having initiated and navigated several national coverage determinations. Most recently, he was an Executive in Residence at Columbia University, where he worked with entrepreneurs and inventors to facilitate the transfer of research innovations from the lab to the market, and to support start-up efforts across therapeutic, diagnostic and device applications. Prior to that, Mr. Rosen held positions of increasing responsibility at Johnson & Johnson, where he focused on oncologic immune cell therapy and circulating tumor cells for research and clinical use. Mr. Rosen holds a BA in Business Studies, from the University of Lincoln, Hull, United Kingdom.
|
Susanne K. Pedersen, PhD
Vice President, Science and Innovation (CSO) and Co-Founder
|
Susanne Pedersen has deep commercial experience focused on biomarker discovery and validation including product concept to successful commercial launch. IVD assay expertise includes molecular diagnostics, proteomics, and immunoassays in esoteric pathology labs as well as point of care testing. Since 2010, her concentrated expertise has been in epigenetics and cell free DNA measurements for cancer detection. Dr. Pedersen is the Inventor of biomarker discovery patents and has a successful track record building cross-functional teams that meet commercial milestones including scale up. B.Sc. (Cell Biology; Southern University of Denmark, 1996); Ph.D. (Molecular Biology; Southern University of Denmark; 2000).
|